Sign in
Taking peoplePhase 3

A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants

Key facts

Who runs it
Hoffmann-La Roche
Where
China20 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
325 people, planned
Started
16 Oct 2026
Expected to end
30 Apr 2027
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Baloxavir marboxil
  • Placebo
Record updated
17 November 2026

Who can take part

Age
5 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Index Participants (Participants With Influenza Virus Infection):
  • First participant in a household with influenza virus infection in the current influenza season
  • Fewer than 6 HHCs
  • Agreement by all household members to participate in the study and comply with the study protocol for the duration of the study
  • Diagnosed as having influenza with positive rapid influenza diagnostic test (RIDT) or polymerase chain reaction (PCR) result
  • Onset of symptoms within 48 hours or less at time of signing Informed Consent Form (ICF)/Assent Form
  • PCR (-) or antigen test (-) for severe acute respiratory virus-coronavirus 2 (SARS-CoV-2) using point-of-care or local laboratory test; HHCs of Index Participants:
  • Lived with the index participant for 48 hours or more prior to informed consent/assent
  • Meet all the following criteria and are judged not to have influenza virus infection by the investigator: body temperature (tympanic) <37.5 degrees Celsius (°C); no influenza-like symptoms (cough, sore throat, headache, nasal discharge/nasal congestion, feverishness or chills, muscle or joint pain, or fatigue) at screening; negative RIDT or PCR result for influenza
  • For participants 12 years of age or older, ability to evaluate influenza symptoms by using a participant influenza symptoms diary; For participants under 12 years of age, capability of parents/caregivers to evaluate influenza symptoms by using a participant influenza symptoms diary
  • PCR (-) or antigen test (-) for SARS-CoV-2 using point-of-care or local laboratory test

Who cannot take part

  • Use of any medications with anti-influenza effect within 30 days prior to screening
  • Exposure to an investigational drug within 30 days or 5 half-lives of the drug prior to screening, whichever is longer; Note: Other protocol-defined inclusion/exclusion criteria may apply
  • Have any underlying diseases requiring systemic (oral or injection), or nasal treatment of antipyretics/analgesics, corticosteroids, or immunosuppressive agents
  • Known allergy and/or history of significant intolerance against baloxavir marboxil
  • HHCs of Index Participants:
  • Diagnosed with influenza during the current influenza season
  • Unable to live with the index patient from screening until Day 10
  • Live with a household member who has any influenza-like symptom(s) other than the index participant on the day of screening
  • Live with household members other than the index participant who was diagnosed with or strongly suspected to have influenza during the current influenza season
  • Immunocompromised

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The main purpose of the study is to evaluate the efficacy of a single dose of baloxavir marboxil compared with placebo in the PEP of influenza virus infection with respect to symptomatic, laboratory-confirmed influenza in participants who are household contacts (HHCs) of participants with influenza (index participants).

The 3 groups in the trial

  • Baloxavir MarboxilTreatment being tested

    HHCs will receive baloxavir marboxil according to their body weight as outlined in the protocol.

  • PlaceboPlacebo, for comparison

    HHCs will receive baloxavir marboxil matching placebo according to their body weight as outlined in the protocol.

  • No InterventionNo study treatment, for comparison

    Index participants will not receive any study treatment but will continue to receive SOC treatment for influenza, as per the local guidelines.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase III, Randomized, Double-blinded, Placebo-controlled Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis of Influenza Virus Infection in Chinese Participants
Record updated
17 November 2026